+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion



Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion



Chest 103(6): 1732-1738



We examined the phenotypes of lymphocytes in the pleural cavity of 23 lung cancer patients without malignant effusion. The ability of those lymphocytes to develop lymphokine-activated killer (LAK) activity and the regulation of LAK by pleural cavity macrophages were also compared with their counterparts in the peripheral blood. Mononuclear cells (MNC) were obtained simultaneously from the blood and by lavage of the pleural cavity of patients with lung cancer. The proportion of the T-cell subset of HLA-DR+ cells was significantly higher in the pleural cavity than in the peripheral blood, but the proportions of CD3+ and CD8+ cells in the pleural cavity were similar to the corresponding proportions in the blood. The proportions of CD4+ and CD16+ cells were lower in the pleural cavity than in the blood. The LAK activity could be developed by MNC from the pleural cavity following incubation with interleukin 2 (IL-2), but the LAK activity of pleural cavity MNC was significantly less than that of peripheral MNC. Pleural cavity lymphocytes alone also developed LAK activity following incubation with IL-2. Pleural macrophages from the patients were regulated to augment in vitro induction of LAK activity by IL-2 from autologous blood lymphocytes and pleural cavity lymphocytes. Lymphocytes in the pleural cavity without malignant pleural effusion could be developed by LAK activity and this activity was augmented by pleural cavity macrophages. The LAK activity developed by pleural cavity lymphocytes was significantly lower than that developed by peripheral blood lymphocytes. However, they can change their population to include cells with higher activities on exposure to IL-2 against the invasion of lung cancer cells into the pleural cavity. Thus, the population of lymphocytes in the pleural cavity of patients with lung cancer without malignant pleural effusion was different from that in malignant pleural effusion.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046973742

Download citation: RISBibTeXText

PMID: 8404092

DOI: 10.1378/chest.103.6.1732


Related references

Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion. Japanese Journal Of Cancer Research. 86(9): 861-866, 1995

Lymphokine il 2 activated killer lak induction and its regulation in malignant pleural effusion of lung cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 30: 373, 1989

Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients. Cancer Immunology Immunotherapy 49(10): 537-543, 2000

Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 42: 877, 2001

Antitumor activity of pleural cavity macrophages and its regulation by pleural cavity lymphocytes in patients with lung cancer. Cancer Research 47(20): 5497-5500, 1987

Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients. Japanese Journal of Cancer Research 81(10): 1012-1020, 1990

Antitumor potential of pleural cavity macrophages in lung cancer patients without malignant effusion. British Journal of Cancer 59(4): 535-539, 1989

A study on lymphokine activated killer lak cell activity of peripheral blood lymphocytes from cancer patients. Journal of Tokyo Women's Medical College 59(9): 1164-1175, 1989

Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients. Internal Medicine 45(11): 715-720, 2006

P3.07-011 Investigation of Autologous Tumor-Killing Effect of Effusion-Associated Lymphocytes in Malignant Pleural Effusion of Lung Cancer. Journal of Thoracic Oncology 12(11): S2301-S2302, 2017

Diagnostic significance of combining telomerase activity with CYFRA21-1 level in differentiating malignant pleural effusion caused by lung cancer from benign pleural effusion. Zhongguo Fei Ai Za Zhi 13(6): 652-654, 2010

Fundamental and clinical studies on adoptive immunotherapy with special reference to postoperative changes in lymphokine activated killer cell activity induced from peripheral blood lymphocytes of gastric and colorectal cancer patients character analysis of various activated lymphocytes and their clinical application. Acta Scholae Medicinalis Universitatis in Gifu 35(6): 1086-1130, 1987

Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Research 47(8): 2184-2187, 1987

Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer. American Journal of Clinical Pathology 92(4): 435-446, 1989

Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. Journal Of Surgical Oncology. 55(3): 179-185, 1994